Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 16:59:51
ChemoMetec (Copenhagen)
Závěr k 13.2.2026 Změna (%) Změna (DKK) Objem obchodů (DKK)
403,40 -0,84 -3,40 19 972 890
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2026
Popis společnosti
Obecné informace
Název společnostiChemoMetec A/S
TickerCHEMM
Kmenové akcie:Ordinary Shares
RICCHEMM.CO
ISINDK0060055861
Poslední známé roční výsledky30.06.2025
Poslední známé čtvrtletní výsledky31.12.2025
Počet zaměstnanců k 31.12.2025 172
Akcie v oběhu k 31.12.2025 17 402 479
MěnaDKK
Kontaktní informace
UliceGydevang 43
MěstoALLEROED
PSČ3450
ZeměDenmark
Kontatní osobaKim Nicolajsen
Funkce kontaktní osobyChief Financial Officer

Business Summary: Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
Financial Summary: BRIEF: For the six months ended 31 December 2025, ChemoMetec A/S revenues decreased 1% to DKR249M. Net income decreased 9% to DKR94M. Revenues reflect Instruments segment decrease of 12% to DKR77M, United States/Canada segment decrease of 10% to DKR135M. Net income also reflects Amortization and Depreciation increase of 70% to DKR15.6M (expense), Other financial income decrease of 73% to DKR1.9M (income).
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment
RBSS2004Industrial Machinery & Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSSoftware Publishers
NAICSInstruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
NAICS2007Analytical Laboratory Instrument Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Software Publishers
NAICS1997Analytical Laboratory Instrument Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Software Publishers
SICAnalytical Instruments
SICDiagnostic Substances
SICPrepackaged Software
SICProcess Control Instruments



  • Poslední aktualizace: 14.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardNiels Thestrup61
Chief Executive OfficerMartin Behrens3213.03.202401.02.2024
Vice Chairman of the BoardMartin Glensbjerg6401.02.202404.08.2006
Chief Financial OfficerKim Nicolajsen4401.07.2024